Melanoma: CheckMate 067-frontline nivolumab improves PFS alone or in combination with ipilimumab

Nature Reviews Clinical Oncology

Volumn 12, Issue 8, 2015, Pages 435-

  Errico, Alessia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; HUMAN; MELANOMA; METASTATIC MELANOMA; MONOTHERAPY; NOTE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; UNSPECIFIED SIDE EFFECT; FEMALE; MALE; SKIN NEOPLASMS;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; MALE; MELANOMA; SKIN NEOPLASMS;

EID: 84938196517     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2015.112     Document Type: Note

References (1)

1. Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. doi:10.1056/NEJMoa1504030